Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lai-Shan Tam, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00668330
First received: April 25, 2008
Last updated: February 10, 2012
Last verified: February 2012
  Purpose

The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role of bone qualities, including micro-architecture, bone remodeling, bone turnover, mineralization and inflammation on bone density and prevalent vertebral fractures in a large population of systemic lupus erythematosus (SLE) patients.

The secondary aim of the study is to evaluate the following parameters in women with steroid induced OP (SIOP) before and after 1 year of treatment using:

  1. The changes in BMD using dual energy X-ray absorptiometry (DXA)
  2. Bone mineralization and architecture in-vivo using a newly available high-resolution human micro-computed tomography (ExtremCT), which can provide us with new insights into how the degree and distribution of mineralization are affected by long-term oral Ibandronate treatment.
  3. Changes in perfusion and marrow edema before and after treatment of Ibandronate using dynamic Magnetic Resonance Imaging (MRI) in these patients with SIOP.
  4. The investigators prospectively evaluate the correlation between the changes in brachial arterial endothelial function and lumbar spine BMD in female lupus patients over the period of 1 year.

Condition Intervention Phase
Systemic Lupus Erythematosus
Drug: Ibandronate+alfacalcidol+calcium
Drug: placebo ibandronate+alfacalcidol+calcium
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment

Resource links provided by NLM:


Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • The primary outcome of Part I study is to investigate the prevalence of low BMD and vertebral fractures. Primary outcome of part II study is the improvement of bone mineral density measured by DEXA. [ Time Frame: baseline and month 12 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT. [ Time Frame: baseline, month 6 and month 12 ] [ Designated as safety issue: Yes ]
    The study will be analyzed using intention-to-treat (ITT) analysis

  • Evaluation of the changes in perfusion and marrow edema using MRI. [ Time Frame: baseline, month 6, month 12 ] [ Designated as safety issue: Yes ]
    The study will be analyzed using intention-to-treat (ITT) analysis


Enrollment: 40
Study Start Date: April 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ibandronate+alfacalcidol+calcium
Bonviva
Drug: Ibandronate+alfacalcidol+calcium
Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
Other Name: Bonviva
Drug: placebo ibandronate+alfacalcidol+calcium
placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
Other Name: placebo Bonviva
Active Comparator: Placebo ibandronate+alfacalcidol+calcium Drug: Ibandronate+alfacalcidol+calcium
Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
Other Name: Bonviva
Drug: placebo ibandronate+alfacalcidol+calcium
placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
Other Name: placebo Bonviva

Detailed Description:

In the first part of the study, 150 consecutive patients with a diagnosis of SLE were included in the study. All patients fulfilled the American College of Rheumatology (ACR) revised criteria for the classification of SLE and provided written informed consent. Data collected at the time of study inclusion were age, disease duration, race, menstrual status, age at menopause, periods of amenorrhea, family history of osteoporosis, ultraviolet (UV) light intolerance, sunshine avoidance, use of sunscreens in the previous year, calculated mean daily dietary calcium intake in the last 3 months, history of (non)vertebral fractures after the age of 25 years, comorbidity, alcohol and tobacco intake, and exercise status.Body weight, height, and body mass index (BMI) were assessed. Disease activity was scored using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 54. Accumulated organ damage was assessed with the SLICC/ ACR damage index (DI) 55. A modified DI score was derived as the DI score excluding osteoporotic fractures as a damage item.BMD measurements of the hip (total hip and femoral neck) and the lumbar spine (L1-4; anteroposterior view) as well as lateral radiographs of the thoracic and lumbar spine (T5-L4)were performed. The prevalence of low BMD and vertebral fractures will be assessed.

In the second part of the study, 40 female SLE patients with steroid induced osteopenia will be enrolled in a 12-month, randomized, parallel-group, controlled study. Patients will receive either oral Ibandronate 150 mg once monthly plus daily alfacalcidol (0.001 mg) or placebo ibandronate once monthly plus daily alfacalcidol(0.001mg).In addition, the intake of dietary calcium will estimate by a questionnaire on the screening visit. All patients will receive a daily calcium supplement(500 mg).

Primary outcome is the improvement of bone mineral density measured by DEXA.

Secondary outcome includes:

  1. Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT.
  2. Evaluation of the changes in perfusion and marrow edema using MRI.
  3. Anti-proliferative and anti-inflammatory action of alfacalcidol using serum level of interleukin-6 (IL-6), transforming growth factor-beta-1, angiotensin-II, as well as urinary levels of TGF and monocyte chemoattractant protein-1 (MCP-1).
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Part I

Inclusion Criteria:

  • Fulfilled the ACR revised criteria for the classification of SLE
  • Provided written informed consent for their participation

Part II

Inclusion Criteria:

  • Have low BMD (T socre < -1 S.D. at the lumbar spine (L1-L4) or total hip) induced by the long-term administration of high-dose corticosteroids.
  • Had been receiving chronic uninterrupted corticosteroid therapy for at least 1 year or had received a corticosteroid dose of at least 5 mg/day.

Exclusion Criteria:

  • Hypocalcaemia, hypercalcaemia, Hypercalciuria, a creatinine clearance of less than 30 ml per minute.
  • A history of nephrolithiasis during the previous five years.
  • A history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis).
  • Had or presence of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism in the year before the study began.
  • Had experienced any previous adverse reaction to bisphosphonate therapy (alendronate, fosamax, ibandronate).
  • With uncontrolled active or recurrent peptic ulcer disease.
  • Receiving therapy (within the last 6 months) known to affect bone metabolism, including:hormone-replacement agents, calcitonin, active vitamin D3 analogues, thiazide diuretics,treatment with bisphosphonates,fluoride treatment within the last 12 mons or for a total duration of 2 years; contraindications to calcium or vitamin D therapy.
  • Pregnant or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00668330

Locations
China
School of Pharmacy CUHK
Hong Kong, China
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: Edmund K Li, MD Chinese University of Hong Kong
  More Information

No publications provided by Chinese University of Hong Kong

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lai-Shan Tam, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT00668330     History of Changes
Other Study ID Numbers: SLE-2007-007
Study First Received: April 25, 2008
Last Updated: February 10, 2012
Health Authority: Hong Kong: Department of Health

Keywords provided by Chinese University of Hong Kong:
Bone mineral density
ibandronate
alfacalcidol

Additional relevant MeSH terms:
Osteoporosis
Lupus Erythematosus, Systemic
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Ibandronic acid
Alfacalcidol
Calcium, Dietary
Diphosphonates
Hydroxycholecalciferols
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on September 18, 2014